A 1985 estimate that 4500 respiratory syncytial virus (RSV)-associated deaths occur annually among US children has not been updated using nationally representative data. Thus, 1979-1997 multiple cause-of-death records for children !5 years old listing bronchiolitis, pneumonia, or any respiratory tract disease were examined. Deaths among children associated with any respiratory disease declined from 4631 in 1979 to 2502 in 1997. During the 19-year study period, 1806 bronchiolitis-associated deaths occurred (annual mean, 95 deaths; range, 66-127 deaths). Of these deaths, 1435 (79%) occurred among infants !1 year old. Congenital heart disease, lung disease, or prematurity was listed in death records of 179 (9.9%), 99 (5.5%), and 76 (4.2%) children dying with bronchiolitis, respectively. By applying published proportions of children hospitalized for bronchiolitis or pneumonia who were RSV-infected to bronchiolitis and pneumonia deaths, it was estimated that р510 RSV-associated deaths occurred annually during the study period, fewer than previously estimated.
RSV infection and bronchiolitis to US childhood mortality have not been assessed recently. A study that compared 1975-1984 respiratory virus isolation data from 10 laboratories with US mortality data among children !5 years old demonstrated a temporal association between winter RSV outbreaks and LRTI deaths among infants 1-11 months old [8] . In 1985, the National Institute of Medicine made the only national estimate of RSVassociated childhood mortality. The institute multiplied a postulated risk of 0.5% for hospitalization among children infected with RSV by a 1984 population projection of children !5 years old [9] . By assuming that 60% of RSV hospitalizations would occur among those !1 year old, the institute estimated that 54,697 infants and 36,465 children 1-4 years old were hospitalized. RSVassociated deaths were calculated by assuming that 5% of children hospitalized with bronchiolitis would die on the basis of mortality among 229 RSV-infected infants hospitalized in a single tertiary-care facility during 1976-1980 [10] . Thus, the institute predicted 2736 RSV-related deaths per year among infants and 1832 among children 1-4 years old.
Since publication of the Institute of Medicine report, several hospital-based studies have documented that mortality among RSV-infected infants with congenital heart disease or other high-risk conditions has decreased markedly, probably because of earlier surgical correction or improvements in critical care [11, 12] . The effect of decreasing mortality among medically complex children with cardiac or lung disease on the overall RSV mortality rate is unknown. Here we describe trends in bronchiolitis-associated deaths among US children and estimate deaths potentially associated with RSV infection by using national data for bronchiolitis and pneumonia deaths. Current estimates of childhood mortality associated with RSV infection are important for economic assessments of prevention interventions, including the cost-effectiveness of the recently licensed humanized murine monoclonal anti-RSV antibody, palivizumab [13] [14] [15] , and of candidate RSV vaccines.
Methods

Sources of data.
We analyzed multiple cause-of-death mortality data compiled by the National Center for Health Statistics, Centers for Disease Control and Prevention, from 1979 through 1997 [16, 17] . A bronchiolitis-associated death was defined as a death for which an International Classification of Diseases (ninth revision; ICD-9) code for acute bronchiolitis (466.1) appeared anywhere on the death record [18] . Since р20 multiple causes-of-death can be listed on a death certificate, use of such a strategy should capture both nosocomial bronchiolitis cases and those deaths for which bronchiolitis was a contributing, but secondary, cause. Records for deaths associated with pneumonia (ICD-9 codes 480-486) and with any respiratory tract disease (ICD-9 codes 460-519) also were examined. The single underlying cause of death for each bronchiolitisassociated death was determined by using computerized selection and modification rules that were developed to ensure international comparability of mortality data [17, 19, 20] .
Because congenital heart disease [10, 21] , chronic lung disease [22] , and premature birth [23] have been associated with increased morbidity among infants hospitalized with RSV infection, these conditions were specifically ascertained among those children who died with bronchiolitis. Prematurity was defined by the appearance of ICD-9 code 765 (disorders relating to short gestation and unspecified low birth weight) anywhere on the death record. Children were classified as having lung disease arising in the perinatal period if any of the following codes appeared in death records: 769 (respiratory distress syndrome), 770.1 (meconium or massive aspiration syndrome), 770.2 (interstitial emphysema and related conditions), 770.3 (pulmonary hemorrhage), 770.4 (primary atelectasis/pulmonary immaturity not otherwise specified), 770.5 (other atelectasis originating in the perinatal period), 770.7 (chronic respiratory disease arising in the perinatal period), 770.8 (other respiratory problems after birth arising in the perinatal period), or 770.9 (unspecified respiratory condition of the fetus and newborn). The following ICD-9 codes were used to define the presence of congenital heart disease: 745 (bulbous cordis anomalies and anomalies of cardiac septal closure), 746 (other congenital anomalies of the heart), 747.0 (patent ductus arteriosus), 747.1 (coarctation of aorta), 747.2 (other anomalies of aorta), 747.3 (anomalies of pulmonary artery), and 747.4 (anomalies of great veins).
Data analysis.
The distribution of bronchiolitis-associated deaths was examined by year, month of death, age (!1 year or 1-4 years), sex, race (white, black, or other), and association with other diagnoses listed in death records. Place of residence was analyzed by using the 4 standard census geographic regions: Northeast, South, Midwest, and West. Among infants, annual bronchiolitis mortality rates were calculated as the number of deaths per 100,000 live births [24] . For children 1-4 years old, denominators were calculated by subtracting births from intercensal population estimates of children !5 years old for the corresponding year [25] .
Poisson regression analysis was used to determine risk ratios (RRs) and to calculate 95% confidence intervals [26] . To detect possible trends in coding of death certificates from 1979 through 1997, the proportions of death records that listed bronchiolitis as the underlying, rather than a multiple, cause of death were compared by calendar year with the Cochran-Armitage test by StatXact 3 software (Cytel Software). A similar method was used to compare the proportions of children dying with bronchiolitis also diagnosed with prematurity, chronic lung disease, or congenital heart disease over time. A 2-tailed was considered statistically significant.
Estimates of RSV-associated deaths. Death certificates often do not specify the etiological agent of many infectious diseases, including bronchiolitis. Therefore, we assumed that the proportions of children dying with bronchiolitis or pneumonia who were infected with RSV were similar to the proportions of children hospitalized in temperate countries for bronchiolitis or pneumonia who were RSV infected [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] . Thus, RSV-related deaths were estimated by multiplying the average annual number of bronchiolitis deaths by 0.3-0.7 and by adding this figure to the average number of pneumonia deaths multiplied by 0.08-0.25.
Results
Bronchiolitis-associated deaths. During the 19-year study period, 1806 bronchiolitis-associated deaths occurred among US children !5 years old (mean, 95 annually; range, 66-127). Of these deaths, 79% (1435) occurred among infants !1 year old. Among infants, the median age at death was 3 months (interquartile range, 2-5 months). Bronchiolitis-associated deaths peaked in January, when 18% of deaths during the study period occurred (figure 1). Most bronchiolitis deaths, 77% among children !1 year old and 71% among children 1-4 years old, occurred during the typical November through April RSV season. The proportion of bronchiolitis-associated deaths during the RSV season was significantly greater among children !1 year than among children 1-4 years old ( ). Patterns P p .02 of monthly mortality did not vary by calendar year or geographic region of residence (data not shown).
Bronchiolitis was the underlying cause of death in 55% of children who died with bronchiolitis (table 1) . Either acute bronchiolitis or acute bronchitis was the underlying cause in 62% of deaths. The proportion of bronchiolitis-associated deaths for which bronchiolitis was determined to be the underlying cause of death did not vary from 1979 through 1997 ( for P p .54 trend). Only 2 other specific respiratory infections were reported as the underlying cause of death in 12% of children who died with bronchiolitis: interstitial pneumonia (2.8%) and pneumonia, organism unspecified (2.4%). Any form of congenital heart disease was the underlying cause of death for 93 children (5.1%), and lung disease arising during the perinatal period was listed as the underlying cause of death for 20 children (1.1%).
Only 3 specific diagnoses were listed on 110% of multiple cause-of-death records among children who died with bronchiolitis: unspecified bronchopneumonia (15%), unspecified pneumonia (13%), and acute bronchitis (11%; table 1). Any form of congenital heart disease was included in multiple cause-ofdeath records for 179 children (9.9%) !5 years old, whereas lung disease was listed as a multiple cause for 99 deaths (5.5%).
Although prematurity was not listed as the underlying cause for any deaths, it was included as a multiple cause of death for 76 children (4.2%). Prematurity and chronic lung disease were listed on bronchiolitis-associated death records with increasing frequency from 1979 through 1997 (P for trend, and P p .02 , respectively). However, congenital heart disease was P p .01 not listed significantly more often as the study period progressed (P for trend, ). P p .59 Mortality rates. From 1979 through 1997, the numbers and rates of infant and childhood deaths for all respiratory tract diseases decreased ( figure 2A) . By 1997, rates among infants and children were у50% lower than the respective 1979 rates. In contrast, the number of bronchiolitis-associated deaths and the mortality rates among children !1 year old and among those 1-4 years old remained relatively stable (figure 2B). Although some year-to-year variability in these rates was demonstrated, particularly among infants, the 1997 rates were similar to the 1979 rates (for infants, 2.2 vs. 2.4 per 100,000 live births; for children !5 years old, 0.57 vs. 0.65 per 100,000 live births).
Although the majority of bronchiolitis-associated deaths occurred among white children (64%), mortality rates were significantly higher among black infants (RR, 2.4) and black children 1-4 years old (RR, 3.0), compared with those of white children (table 2) . Male infants were 1.5 times more likely to die with bronchiolitis than were female infants; however, boys 1-4 years old were not at a significantly increased risk of dying with bronchiolitis. Children in the South faced the greatest risk of dying with bronchiolitis (RR, 1.6), compared with that of infants in the Northeast, who had the lowest rates.
Estimates of RSV-associated mortality. A mean of 1772 pneumonia-associated deaths occurred annually among children !5 years old during the study period; of these, 1261 deaths (71%) occurred among infants !1 year old. To estimate RSVassociated mortality, we multiplied the annual average of pneumonia deaths by 0.08-0.25 and added this number to the annual average of 95 bronchiolitis deaths multiplied by 0.3-0.7. Under these assumptions, we estimated that 171-510 RSV-associated deaths occurred annually among young children during the study period.
Discussion
We found that bronchiolitis-associated mortality rates among children were relatively stable from 1979 through 1997, with no suggestion of a consistent increase or decrease. In contrast, childhood deaths associated with any respiratory disease decreased steadily. Fewer than 3000 respiratory deaths occurred annually during the last 4 years of the study period, 1500 fewer than the 4500 estimated for RSV alone by the Institute of Medicine.
Most children dying with bronchiolitis were not concurrently diagnosed with underlying prematurity or pulmonary or cardiac conditions. This finding suggests that the majority of RSV-related deaths do not occur among children who are presumed to be at high risk for severe RSV LRTIs. Prophylactic therapy with either RSV-enriched human immunoglobulin or a humanized murine monoclonal anti-F protein antibody is available for premature infants and children with chronic lung disease [13] . However, our findings suggest that appropriate use of these antibody therapies will not prevent the majority of RSV-associated deaths.
Although the only specific ICD-9 code for RSV-related disease (RSV pneumonia, code 480.1) appeared infrequently in the records of children who died with bronchiolitis (1.6%), the seasonal pattern of deaths and the fact that 79% of these deaths occurred among infants provide evidence that RSV is the primary virus associated with bronchiolitis deaths. Our findings, that male infants are more likely to die with bronchiolitis than are female infants and that black children and those living in the South are at the greatest risk of bronchiolitis-associated death, are consistent with results of studies of children hospitalized with RSV infection. Boys are ∼1.5 times more likely than are girls to be hospitalized with RSV infections [4, 37] , and lower socioeconomic status is associated with an increased risk for hospitalization with RSV [6, 38] . Black race and residence in the South have been used as crude surrogates for lower socioeconomic status among US children [39] .
We estimate that 200-500 young US children annually die with RSV-associated deaths, substantially fewer than the 4500 deaths estimated by the Institute of Medicine in 1985 [9] , the only other national estimate of the RSV mortality burden. We also found that ∼80% of these deaths occur among infants, a higher proportion than the 60% assumed in 1985. A recent estimate suggests that 1500-6700 annual pneumonia deaths among adults у65 years old may be RSV associated [40] . Therefore, considerably more RSV-related deaths appear to occur among the elderly than among children !5 years old. The fact that fewer than 3000 respiratory deaths of all types currently occur among young children may constitute the most compelling evidence that the 1985 Institute of Medicine RSV mortality estimates are too high to be applicable to the current US population of children. The 1985 figures were derived by applying mortality data collected during 1976-1980 from a single tertiary-care facility (5%) to the US population of children. More recent hospital-based studies indicate that mortality from RSV-associated illnesses among high-risk children has decreased since then [11, 12] . In addition, many children with common childhood diseases (e.g., bronchiolitis) are hospitalized in general community hospitals. The application of morbidity and mortality estimates derived from tertiary-care centers, which typically care for more severely ill children, to the general population may overestimate serious sequelae, including death. For example, initial reports from academic medical centers of children evaluated for febrile seizures indicated recurrence rates as high as 71% and a markedly increased risk for later nonfebrile seizures [41] . Subsequent population-based studies found lower febrile seizure recurrence rates (29%-35%) and only a nominally increased risk for epilepsy among children followed up after an initial febrile seizure [41] . Other examples of referral bias in observational studies conducted within tertiary-care facilities include clinical trials and outcomes studies among patients with multiple sclerosis [42] and diabetes mellitus [43] .
An interesting finding in our analysis is that, although mortality rates for all respiratory disease deaths among children !5 years old decreased during the study period, bronchiolitisassociated mortality rates remained essentially unchanged. In contrast, bronchiolitis-associated hospitalization rates increased substantially from 1980 through 1996 [4] . Thus, increasing hospitalization rates have not been accompanied by concomitant increases in mortality rates. These findings prompt у2 hypotheses: (1) improved medical and surgical care has decreased the proportion of children hospitalized with bronchiolitis who die, and (2) children with less severe bronchiolitis have had an increased chance of hospitalization since 1980.
Mortality among high-risk RSV-infected children hospitalized in academic centers decreased during the study period [11, 12] . As the study period progressed, we believe that less severely ill infants may have been more likely to be hospitalized for bronchiolitis. Changes in the evaluation and monitoring of young children with lower respiratory tract illnesses could result in increased bronchiolitis hospitalizations, without affecting mortality rates. For example, expansion of pulse oximetry use in the evaluation of wheezing infants might lower the threshold for hospitalization among RSV-infected children who have mild hypoxia but who are not at risk of impending respiratory failure [4] . Also, pathology studies linking viral respiratory infection to sudden infant death syndrome (SIDS) cases [44] and epidemiological associations between SIDS deaths and temporal patterns of RSV detection [8] may have compelled health care providers to hospitalize more young RSV-infected infants for apnea observation as pediatric monitoring methods improved.
Our population-based study has several limitations. One is the lack of ICD-9 codes that specifically and completely capture RSV-associated mortality. Therefore, we were forced to estimate the RSV mortality burden by multiplying deaths associated with bronchiolitis or pneumonia by the proportions of these diagnoses associated with RSV infection among hospitalized children. Some children whose deaths were related to RSV infection may not have been included in the death records we used. For example, it is possible that infants dying with chronic lung disease during the winter months may have had undocumented respiratory viral infections that contributed to their mortality. However, too few children currently die in the United States with diagnoses such as bronchopulmonary dysplasia to account for the differences between our estimates and those of the Institute of Medicine. Finally, the presence of comorbid conditions may have been underestimated in death certificate records. On the basis of a previous study, we almost certainly underestimated the prevalence of prematurity [45] . For other conditions that we were specifically interested in, however, death certificates appear to record underlying conditions adequately. For example, congenital heart disease, when examined as a single entity, is completely captured in death records, although specific diagnoses (e.g., tetralogy of Fallot) are not adequately identified [46] .
A variety of therapies for bronchiolitis and RSV disease were introduced or became more widely used during the study period, including ribavirin, bronchodilators, and corticosteroids [47] . However, increasing use of these drugs did not lead to decreasing rates of childhood bronchiolitis deaths. Corticosteroid treatment of bronchiolitis and RSV infection was found ineffective in 2 large, well-designed clinical trials [48, 49] . Use of ribavirin in severely ill patients with RSV disease may not improve outcomes [50, 51] , and routine use of bronchodilators in less severely ill patients remains controversial [52, 53] . An apparent lack of an effect of more medication use on bronchiolitis-associated morbidity has also been demonstrated among hospitalized children. Canadian children hospitalized with RSV infections in 12 pediatric tertiary-care centers experienced similar lengths of stay at each center, despite considerable variation in medication use, particularly among previously healthy children [54] .
In summary, RSV-associated mortality among young US children is considerably lower than previously estimated. It is unlikely that currently available prevention or therapeutic interventions will substantially influence RSV-associated mortality among young children. If RSV-associated mortality is to be reduced, effective RSV vaccines that can be administered safely to infants and the elderly are needed.
